GPCR functional selectivity has therapeutic impact

被引:162
作者
Mailman, Richard B. [1 ]
机构
[1] Univ N Carolina, Sch Med, Neurosci Hosp, Chapel Hill, NC 27599 USA
关键词
D O I
10.1016/j.tips.2007.06.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Many in vitro data show that some ligands can cause the differential activation of signaling pathways mediated by a single receptor (termed 'functional selectivity'). It remains unclear, however, whether functionally selective properties are meaningful in vivo. Data obtained with experimental compounds that are functionally selective at the dopamine D(2L) receptor in vitro suggest that these properties might predict atypical behavioral actions. Moreover, the antipsychotic drug aripiprazole is commonly thought to be a D(2) partial agonist, but data clearly show that aripiprazole is functionally selective in vitro. It is proposed that the effects of aripiprazole in animal models and humans can be reconciled only with its functionally selective D(2) properties, not its partial D(2) agonism. Together, these data provide support for the hypothesis that compounds with functionally selective properties in vitro are likely to have novel actions in vivo, opening doors to new avenues of drug discovery.
引用
收藏
页码:390 / 396
页数:7
相关论文
共 59 条
[1]  
[Anonymous], 1997, The dopamine receptors
[2]  
ARIENS EJ, 1954, ARCH INT PHARMACOD T, V99, P32
[3]  
ASIMOV I, 1971, MAGAZINE FANTASY SCI
[4]   EFFECT OF D1-RECEPTOR STIMULATION IN NORMAL AND MPTP MONKEYS [J].
BEDARD, PJ ;
BOUCHER, R .
NEUROSCIENCE LETTERS, 1989, 104 (1-2) :223-228
[5]   TRANS-10,11-DIHYDROXY-5,6,6A,7,8,12B-HEXAHYDROBENZO[A]PHENANTHRIDINE - A HIGHLY POTENT SELECTIVE DOPAMINE-D1 FULL AGONIST [J].
BREWSTER, WK ;
NICHOLS, DE ;
RIGGS, RM ;
MOTTOLA, DM ;
LOVENBERG, TW ;
LEWIS, MH ;
MAILMAN, RB .
JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (06) :1756-1764
[6]   Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors [J].
Burris, KD ;
Molski, TF ;
Xu, C ;
Ryan, E ;
Tottori, K ;
Kikuchi, T ;
Yocca, FD ;
Molinoff, PB .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (01) :381-389
[7]  
CARLSSON A, 1963, ACTA PHARMACOL TOX, V20, P140
[8]   CONFORMATIONAL-ANALYSIS AND MOLECULAR MODELING OF 1-PHENYL-1,2,3,4-TETRAHYDROISOQUINOLINES, 4-PHENYL-1,2,3,4-TETRAHYDROISOQUINOLINES, AND 1-BENZYL-1,2,3,4-TETRAHYDROISOQUINOLINES AS D1 DOPAMINE RECEPTOR LIGANDS [J].
CHARIFSON, PS ;
BOWEN, JP ;
WYRICK, SD ;
HOFFMAN, AJ ;
CORY, M ;
MCPHAIL, AT ;
MAILMAN, RB .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (09) :2050-2058
[9]   SYNTHESIS AND PHARMACOLOGICAL CHARACTERIZATION OF 1-PHENYL-1,2,3,4-TETRAHYDROISOQUINOLINE, 4-PHENYL-1,2,3,4-TETRAHYDROISOQUINOLINE, AND 1-BENZYL-1,2,3,4-TETRAHYDROISOQUINOLINE AS DOPAMINE RECEPTOR LIGANDS [J].
CHARIFSON, PS ;
WYRICK, SD ;
HOFFMAN, AJ ;
SIMMONS, RMA ;
BOWEN, JP ;
MCDOUGALD, DL ;
MAILMAN, RB .
JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (10) :1941-1946
[10]  
CORSINI GU, 1981, NEUROPHARMACOLOGY, V20, P1309